RANDAL J KIRK Insider Trading Transactions
Get free email notifications about insider trading for RANDAL J KIRK.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of RANDAL J KIRK. RANDAL J KIRK is Director in CLINICAL DATA INC ($NOVI) and 10% Owner in AmpliPhi Biosciences Corp ($APHB) and 10% Owner in Fibrocell Science, Inc. ($FCSC) and 10% Owner in SOLIGENIX, INC. ($DOR) and 10% Owner in Synthetic Biologics, Inc. ($SYN) and 10% Owner in TRANSGENOMIC INC ($TBIO) and Director in ZIOPHARM ONCOLOGY INC ($ZIOP) and 10% Owner in HALOZYME THERAPEUTICS INC ($GYHT) and Director in HALOZYME THERAPEUTICS INC ($GYHT) and 10% Owner in ORAGENICS INC ($OGEN) and 10% Owner in INTREXON CORP ($XON) and Chief Executive Officer in INTREXON CORP ($XON) and Director in INTREXON CORP ($XON) and Executive Chairman in INTREXON CORP ($XON) and 10% Owner in HISTOGENICS CORP ($HSGX) and 10% Owner in AquaBounty Technologies, Inc. ($AQB).
Latest Insider Trading Transactions of RANDAL J KIRK
Sentiment: All, AQB, APHB, NOVI, FCSC, GYHT, HSGX, OGEN, XON, PRPO, SNGX, SYN, ZIOP
Page: < prev 1 2 3 4 5 6 6 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 21 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.69 | 53,002 | 248,579 | 16,977,975 | 16.9 M to 17 M (+0.31 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.59 | 62,810 | 288,298 | 846,019 | 783.2 K to 846 K (+8.02 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.37 | 29,500 | 128,915 | 783,209 | 753.7 K to 783.2 K (+3.91 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.25 | 75,386 | 320,391 | 753,709 | 678.3 K to 753.7 K (+11.11 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.59 | 125,620 | 576,596 | 381,605 | 256 K to 381.6 K (+49.07 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.37 | 59,000 | 257,830 | 255,985 | 197 K to 256 K (+29.95 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.25 | 150,773 | 640,785 | 196,985 | 46.2 K to 197 K (+326.26 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.59 | 125,620 | 576,596 | 381,605 | 256 K to 381.6 K (+49.07 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.37 | 59,000 | 257,830 | 255,985 | 197 K to 256 K (+29.95 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.25 | 150,773 | 640,785 | 196,985 | 46.2 K to 197 K (+326.26 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.59 | 2,544 | 11,677 | 145,395 | 142.9 K to 145.4 K (+1.78 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.37 | 1,195 | 5,222 | 142,851 | 141.7 K to 142.9 K (+0.84 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.25 | 3,053 | 12,975 | 141,656 | 138.6 K to 141.7 K (+2.20 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.59 | 5,260 | 24,143 | 97,266 | 92 K to 97.3 K (+5.72 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.37 | 2,471 | 10,798 | 92,006 | 89.5 K to 92 K (+2.76 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.25 | 6,314 | 26,835 | 89,535 | 83.2 K to 89.5 K (+7.59 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.59 | 7,050 | 32,360 | 143,318 | 136.3 K to 143.3 K (+5.17 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.37 | 3,311 | 14,469 | 136,268 | 133 K to 136.3 K (+2.49 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.25 | 8,462 | 35,964 | 132,957 | 124.5 K to 133 K (+6.80 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.59 | 25,611 | 117,554 | 1,044,902 | 1 M to 1 M (+2.51 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.37 | 12,029 | 52,567 | 1,019,291 | 1 M to 1 M (+1.19 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.25 | 30,739 | 130,641 | 1,007,262 | 976.5 K to 1 M (+3.15 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.59 | 58,994 | 270,782 | 1,098,700 | 1 M to 1.1 M (+5.67 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.37 | 27,708 | 121,084 | 1,039,706 | 1 M to 1 M (+2.74 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.25 | 70,807 | 300,930 | 1,011,998 | 941.2 K to 1 M (+7.52 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.59 | 7,176 | 32,938 | 171,860 | 164.7 K to 171.9 K (+4.36 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.37 | 3,370 | 14,727 | 164,684 | 161.3 K to 164.7 K (+2.09 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.25 | 8,613 | 36,605 | 161,314 | 152.7 K to 161.3 K (+5.64 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.59 | 25,234 | 115,824 | 946,910 | 921.7 K to 946.9 K (+2.74 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.37 | 11,852 | 51,793 | 921,676 | 909.8 K to 921.7 K (+1.30 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.25 | 30,287 | 128,720 | 909,824 | 879.5 K to 909.8 K (+3.44 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.59 | 56,733 | 260,404 | 966,043 | 909.3 K to 966 K (+6.24 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.37 | 26,646 | 116,443 | 909,310 | 882.7 K to 909.3 K (+3.02 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.25 | 68,093 | 289,395 | 882,664 | 814.6 K to 882.7 K (+8.36 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.59 | 7,474 | 34,306 | 171,702 | 164.2 K to 171.7 K (+4.55 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.37 | 3,511 | 15,343 | 164,228 | 160.7 K to 164.2 K (+2.18 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.25 | 8,971 | 38,127 | 160,717 | 151.7 K to 160.7 K (+5.91 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.59 | 275,001 | 1,262,255 | 16,924,973 | 16.6 M to 16.9 M (+1.65 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.37 | 129,158 | 564,420 | 16,649,972 | 16.5 M to 16.6 M (+0.78 %) |
May 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 4.25 | 330,060 | 1,402,755 | 16,520,814 | 16.2 M to 16.5 M (+2.04 %) |
May 02 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 0.00 | 508,617 | 0 | 2,091,141 | 1.6 M to 2.1 M (+32.14 %) |
May 02 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 4.56 | 43,887 | 200,125 | 16,190,754 | 16.1 M to 16.2 M (+0.27 %) |
Apr 03 2019 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Sell | S | 0.65 | 69,161 | 44,955 | 165,332 | 234.5 K to 165.3 K (-29.49 %) |
Apr 03 2019 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Sell | S | 0.65 | 26,080 | 16,952 | 62,342 | 88.4 K to 62.3 K (-29.49 %) |
Apr 03 2019 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Sell | S | 0.66 | 9,909 | 6,540 | 234,493 | 244.4 K to 234.5 K (-4.05 %) |
Apr 03 2019 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Sell | S | 0.66 | 3,737 | 2,466 | 88,422 | 92.2 K to 88.4 K (-4.05 %) |
Apr 03 2019 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Sell | S | 0.67 | 30,265 | 20,278 | 244,402 | 274.7 K to 244.4 K (-11.02 %) |
Apr 03 2019 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Sell | S | 0.67 | 11,413 | 7,647 | 92,159 | 103.6 K to 92.2 K (-11.02 %) |
Apr 03 2019 | SYN | Synthetic Biologic ... | KIRK RANDAL J | 10% Owner | Sell | S | 0.65 | 69,161 | 44,955 | 165,332 | 234.5 K to 165.3 K (-29.49 %) |
Apr 03 2019 | SYN | Synthetic Biologic ... | KIRK RANDAL J | 10% Owner | Sell | S | 0.65 | 26,080 | 16,952 | 62,342 | 88.4 K to 62.3 K (-29.49 %) |
Apr 03 2019 | SYN | Synthetic Biologic ... | KIRK RANDAL J | 10% Owner | Sell | S | 0.66 | 9,909 | 6,540 | 234,493 | 244.4 K to 234.5 K (-4.05 %) |
Apr 03 2019 | SYN | Synthetic Biologic ... | KIRK RANDAL J | 10% Owner | Sell | S | 0.66 | 3,737 | 2,466 | 88,422 | 92.2 K to 88.4 K (-4.05 %) |
Apr 03 2019 | SYN | Synthetic Biologic ... | KIRK RANDAL J | 10% Owner | Sell | S | 0.67 | 30,265 | 20,278 | 244,402 | 274.7 K to 244.4 K (-11.02 %) |
Apr 03 2019 | SYN | Synthetic Biologic ... | KIRK RANDAL J | 10% Owner | Sell | S | 0.67 | 11,413 | 7,647 | 92,159 | 103.6 K to 92.2 K (-11.02 %) |
Feb 04 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 7.66 | 26,109 | 199,995 | 16,083,751 | 16.1 M to 16.1 M (+0.16 %) |
Jan 15 2019 | HSGX | HISTOGENICS CORP | KIRK RANDAL J | 10% Owner | Sell | S | 0.15 | 345,897 | 51,885 | 1,692,366 | 2 M to 1.7 M (-16.97 %) |
Jan 15 2019 | HSGX | HISTOGENICS CORP | KIRK RANDAL J | 10% Owner | Sell | S | 0.16 | 400,507 | 64,081 | 2,038,263 | 2.4 M to 2 M (-16.42 %) |
Jan 15 2019 | HSGX | HISTOGENICS CORP | KIRK RANDAL J | 10% Owner | Sell | S | 0.17 | 251,800 | 42,806 | 2,438,770 | 2.7 M to 2.4 M (-9.36 %) |
Jan 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Sell | S | 0.15 | 345,897 | 51,885 | 1,692,366 | 2 M to 1.7 M (-16.97 %) |
Jan 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Sell | S | 0.16 | 400,507 | 64,081 | 2,038,263 | 2.4 M to 2 M (-16.42 %) |
Jan 15 2019 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Sell | S | 0.17 | 251,800 | 42,806 | 2,438,770 | 2.7 M to 2.4 M (-9.36 %) |
Jan 08 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Option Exercise | A | 0.00 | 13,775 | 0 | 13,775 | |
Jan 08 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 0.00 | 13,774 | 0 | 16,057,642 | 16 M to 16.1 M (+0.09 %) |
Jan 08 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Option Exercise | A | 0.00 | 13,775 | 0 | 13,775 | |
Jan 08 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 0.00 | 13,774 | 0 | 16,057,642 | 16 M to 16.1 M (+0.09 %) |
Jan 02 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 6.54 | 30,581 | 200,000 | 16,043,868 | 16 M to 16 M (+0.19 %) |
Jan 02 2019 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 8.29 | 96,501 | 799,993 | 1,582,524 | 1.5 M to 1.6 M (+6.49 %) |
Dec 03 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 0.00 | 20,408 | 0 | 16,013,287 | 16 M to 16 M (+0.13 %) |
Dec 03 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 0.00 | 77,594 | 0 | 1,486,023 | 1.4 M to 1.5 M (+5.51 %) |
Nov 23 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | J | 0.00 | 7,537 | 0 | 83,221 | 75.7 K to 83.2 K (+9.96 %) |
Nov 23 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | J | 0.00 | 10,314 | 0 | 124,495 | 114.2 K to 124.5 K (+9.03 %) |
Nov 23 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | J | 0.00 | 46,212 | 0 | 46,212 | 0 to 46.2 K |
Nov 23 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | J | 0.00 | 46,212 | 0 | 46,212 | 0 to 46.2 K |
Nov 23 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | J | 0.00 | 36,097 | 0 | 976,523 | 940.4 K to 976.5 K (+3.84 %) |
Nov 23 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | J | 0.00 | 90,836 | 0 | 941,191 | 850.4 K to 941.2 K (+10.68 %) |
Nov 23 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | J | 0.00 | 12,694 | 0 | 152,701 | 140 K to 152.7 K (+9.07 %) |
Nov 23 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | J | 0.00 | 3,570 | 0 | 138,603 | 135 K to 138.6 K (+2.64 %) |
Nov 23 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | J | 0.00 | 36,493 | 0 | 879,537 | 843 K to 879.5 K (+4.33 %) |
Nov 23 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | J | 0.00 | 94,009 | 0 | 814,571 | 720.6 K to 814.6 K (+13.05 %) |
Nov 23 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | J | 0.00 | 12,694 | 0 | 151,746 | 139.1 K to 151.7 K (+9.13 %) |
Nov 02 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 11.56 | 17,301 | 200,000 | 15,992,879 | 16 M to 16 M (+0.11 %) |
Nov 02 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 14.42 | 55,478 | 799,993 | 1,408,429 | 1.4 M to 1.4 M (+4.10 %) |
Oct 29 2018 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Option Exercise | X | 2.00 | 1,538,461 | 3,076,922 | 0 | |
Oct 29 2018 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | X | 2.00 | 1,538,461 | 3,076,922 | 8,239,199 | 6.7 M to 8.2 M (+22.96 %) |
Oct 29 2018 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Option Exercise | X | 2.00 | 1,538,461 | 3,076,922 | 0 | |
Oct 29 2018 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | X | 2.00 | 1,538,461 | 3,076,922 | 8,239,199 | 6.7 M to 8.2 M (+22.96 %) |
Oct 09 2018 | XON | INTREXON CORP | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 130,849 | 0 | 0 | |
Oct 09 2018 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 130,849 | 0 | 0 | |
Oct 09 2018 | XON | INTREXON CORP | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 130,849 | 0 | 0 | |
Oct 09 2018 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 130,849 | 0 | 0 | |
Oct 01 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 17.22 | 11,614 | 199,993 | 15,975,578 | 16 M to 16 M (+0.07 %) |
Oct 01 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 14.31 | 55,904 | 799,986 | 1,352,951 | 1.3 M to 1.4 M (+4.31 %) |
Sep 28 2018 | XON | INTREXON CORP | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,295 | 0 | 130,849 | |
Sep 28 2018 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,295 | 0 | 130,849 | |
Sep 05 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 15.38 | 13,003 | 199,986 | 15,963,964 | 16 M to 16 M (+0.08 %) |
Sep 05 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 13.74 | 58,224 | 799,998 | 1,297,047 | 1.2 M to 1.3 M (+4.70 %) |
Aug 31 2018 | XON | INTREXON CORP | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,282 | 0 | 129,554 | |
Aug 31 2018 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,282 | 0 | 129,554 | |
Aug 30 2018 | TBIO | Precipio, Inc. | KIRK RANDAL J | 10% Owner | Sell | S | 0.41 | 500 | 205 | 27,151 | 27.7 K to 27.2 K (-1.81 %) |
Aug 30 2018 | TBIO | Precipio, Inc. | KIRK RANDAL J | 10% Owner | Sell | S | 0.41 | 4,920 | 2,017 | 266,904 | 271.8 K to 266.9 K (-1.81 %) |
Aug 30 2018 | TBIO | Precipio, Inc. | KIRK RANDAL J | 10% Owner | Sell | S | 0.41 | 9,340 | 3,829 | 506,657 | 516 K to 506.7 K (-1.81 %) |
Aug 30 2018 | TBIO | Precipio, Inc. | KIRK RANDAL J | 10% Owner | Sell | S | 0.41 | 9,840 | 4,034 | 533,809 | 543.6 K to 533.8 K (-1.81 %) |
Aug 28 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 18.02 | 256,860 | 4,628,617 | 1,897,610 | 2.2 M to 1.9 M (-11.92 %) |
Aug 28 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 18.22 | 64,996 | 1,184,227 | 2,154,470 | 2.2 M to 2.2 M (-2.93 %) |
Aug 28 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 18.20 | 61,428 | 1,117,990 | 2,219,466 | 2.3 M to 2.2 M (-2.69 %) |
Aug 28 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 18.02 | 175,389 | 3,160,510 | 3,900,919 | 4.1 M to 3.9 M (-4.30 %) |
Aug 28 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 18.22 | 44,381 | 808,622 | 4,076,308 | 4.1 M to 4.1 M (-1.08 %) |
Aug 28 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 18.20 | 41,944 | 763,381 | 4,120,689 | 4.2 M to 4.1 M (-1.01 %) |
Aug 23 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 18.48 | 149,353 | 2,760,043 | 2,280,894 | 2.4 M to 2.3 M (-6.15 %) |
Aug 23 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.49 | 464,624 | 8,126,274 | 2,430,247 | 2.9 M to 2.4 M (-16.05 %) |
Aug 23 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.15 | 95,819 | 1,643,296 | 2,894,871 | 3 M to 2.9 M (-3.20 %) |
Aug 23 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 18.48 | 101,982 | 1,884,627 | 4,162,633 | 4.3 M to 4.2 M (-2.39 %) |
Aug 23 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.49 | 317,257 | 5,548,825 | 4,264,615 | 4.6 M to 4.3 M (-6.92 %) |
Aug 23 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.15 | 65,427 | 1,122,073 | 4,581,872 | 4.6 M to 4.6 M (-1.41 %) |
Aug 16 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.24 | 56,668 | 976,956 | 2,985,054 | 3 M to 3 M (-1.86 %) |
Aug 16 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.15 | 54,397 | 932,909 | 3,041,722 | 3.1 M to 3 M (-1.76 %) |
Aug 16 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.36 | 180,154 | 3,127,473 | 3,096,119 | 3.3 M to 3.1 M (-5.50 %) |
Aug 16 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.24 | 38,695 | 667,102 | 4,643,451 | 4.7 M to 4.6 M (-0.83 %) |
Aug 16 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.15 | 37,144 | 637,020 | 4,682,146 | 4.7 M to 4.7 M (-0.79 %) |
Aug 16 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.36 | 123,014 | 2,135,523 | 4,719,290 | 4.8 M to 4.7 M (-2.54 %) |
Aug 10 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.08 | 120,606 | 2,059,950 | 3,276,273 | 3.4 M to 3.3 M (-3.55 %) |
Aug 10 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.48 | 132,591 | 2,317,691 | 3,396,879 | 3.5 M to 3.4 M (-3.76 %) |
Aug 10 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.52 | 87,185 | 1,527,481 | 3,529,470 | 3.6 M to 3.5 M (-2.41 %) |
Aug 10 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.08 | 82,353 | 1,406,589 | 4,842,304 | 4.9 M to 4.8 M (-1.67 %) |
Aug 10 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.48 | 90,536 | 1,582,569 | 4,924,657 | 5 M to 4.9 M (-1.81 %) |
Aug 10 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.52 | 59,533 | 1,043,018 | 5,015,193 | 5.1 M to 5 M (-1.17 %) |
Aug 01 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 14.66 | 13,642 | 199,992 | 15,950,961 | 15.9 M to 16 M (+0.09 %) |
Aug 01 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 15.38 | 52,015 | 799,991 | 1,238,823 | 1.2 M to 1.2 M (+4.38 %) |
Jul 31 2018 | XON | INTREXON CORP | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,270 | 0 | 128,272 | |
Jul 31 2018 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,270 | 0 | 128,272 | |
Jul 27 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 16.90 | 29,074 | 491,351 | 3,616,655 | 3.6 M to 3.6 M (-0.80 %) |
Jul 27 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.30 | 89,136 | 1,542,053 | 3,645,729 | 3.7 M to 3.6 M (-2.39 %) |
Jul 27 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.32 | 61,741 | 1,069,354 | 3,734,865 | 3.8 M to 3.7 M (-1.63 %) |
Jul 27 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 16.90 | 19,853 | 335,516 | 5,074,726 | 5.1 M to 5.1 M (-0.39 %) |
Jul 27 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.30 | 60,864 | 1,052,947 | 5,094,579 | 5.2 M to 5.1 M (-1.18 %) |
Jul 27 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.32 | 42,159 | 730,194 | 5,155,443 | 5.2 M to 5.2 M (-0.81 %) |
Jul 06 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 13.37 | 1,121,914 | 14,999,990 | 15,937,319 | 14.8 M to 15.9 M (+7.57 %) |
Jul 06 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 13.37 | 6,357,517 | 85,000,002 | 14,140,139 | 7.8 M to 14.1 M (+81.69 %) |
Jul 02 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 13.94 | 14,347 | 199,997 | 14,815,405 | 14.8 M to 14.8 M (+0.10 %) |
Jul 02 2018 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 16.15 | 49,535 | 799,990 | 1,186,808 | 1.1 M to 1.2 M (+4.36 %) |
Jun 29 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 16.97 | 72,753 | 1,234,618 | 3,796,606 | 3.9 M to 3.8 M (-1.88 %) |
Jun 29 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 16.97 | 72,753 | 1,234,618 | 3,796,606 | 3.9 M to 3.8 M (-1.88 %) |
Jun 29 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 16.99 | 76,291 | 1,296,184 | 3,869,359 | 3.9 M to 3.9 M (-1.93 %) |
Jun 29 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 16.99 | 76,291 | 1,296,184 | 3,869,359 | 3.9 M to 3.9 M (-1.93 %) |
Jun 29 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.34 | 31,795 | 551,325 | 3,945,650 | 4 M to 3.9 M (-0.80 %) |
Jun 29 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 17.34 | 31,795 | 551,325 | 3,945,650 | 4 M to 3.9 M (-0.80 %) |
Jun 29 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 16.97 | 49,678 | 843,036 | 5,197,602 | 5.2 M to 5.2 M (-0.95 %) |
Jun 29 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 16.97 | 49,678 | 843,036 | 5,197,602 | 5.2 M to 5.2 M (-0.95 %) |
Jun 29 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 16.99 | 52,094 | 885,077 | 5,247,280 | 5.3 M to 5.2 M (-0.98 %) |
Jun 29 2018 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | 10% Owner | Sell | S | 16.99 | 52,094 | 885,077 | 5,247,280 | 5.3 M to 5.2 M (-0.98 %) |